Human umbilical arteries converted arachidonic acid to three hydroxyeicosatetraenoic acids (HETEs) as well as prostaglandins. The mono-HETEs have been identified by reverse-phase high pressure liquid chromatography and gas chromatographymass spectroscopy as 15-HETE and li-HETE. 15 To investigate whether our in vitro finding that 15-HETE inhibited prostacyclin production could be relevant to the in vivo situation, our final studies were performed on vasculature obtained from the diabetic milieu. We found that the production of 15-HETE was significantly increased in vasculature obtained from the infant of the diabetic mother (1.14±0.26 pmol/mg) when compared to control neonates (0.77±0.22; P < 0.01). A concomitant decrease in prostacyclin production was seen (51.6±12.6 pmol/mg in infants of diabetic mothers vs. 71±22.3 in controls). Moreover, an inverse correlation between these two eicosanoids was also noted. Our results suggest a potential in vivo regulatory role for 15-HETE on prostacyclin production.
Introduction
Human umbilical arteries converted arachidonic acid to three hydroxyeicosatetraenoic acids (HETEs) as well as prostaglandins. The mono-HETEs have been identified by reverse-phase high pressure liquid chromatography and gas chromatographymass spectroscopy as 15-HETE and li-HETE. 15 -HETE in arterial segments appears to be derived mainly via the 15-lipoxygenase pathway, whereas ll-HETE, and the presumed di-HETE(s) were products of cyclooxygenase. Nordihydroguaiaretic acid, a lipoxygenase inhibitor, stimulated prostanoid production with a concomitant inhibition of 15-HETE formation. These results suggested that 15-HETE may function as an endogenous regulator of prostacyclin. In human umbilical arterial microsomes, 15-HETE was found to inhibit 6-keto-prostaglandin Fli and total prostanoid production in a concentration-dependent manner (median inhibition constant [ICsoj of 52±3 and 63±4 AM, respectively). The relative distribution of prostaglandins, however, remained unaffected, indicating that the site of action was cyclooxygenase. Kinetic analysis revealed that 15-HETE was a competitive inhibitor of the enzyme. Although no changes in maximum velocity occurred, the apparent Km was significantly different (93±6.9 MM 11 SD] for control vs. 37 .6±17.7 AM for the 15-HETE-treated enzyme). Furthermore, the inhibitory effect of 15-HETE on prostacyclin production was confirmed using cultured bovine endothelial cells. In this cell system, not only did 15 -HETE inhibit endogenous prostacyclin production, but also the conversion of exogenous 11-_4Clarachidonic acid to prostacyclin (IC5o of 40±17 MM). No effect on arachidonic acid release was noted.
To investigate whether our in vitro finding that 15-HETE inhibited prostacyclin production could be relevant to the in vivo situation, our final studies were performed on vasculature obtained from the diabetic milieu. We found that the production of 15 -HETE was significantly increased in vasculature obtained from the infant of the diabetic mother (1.14±0.26 pmol/mg) when compared to control neonates (0.77±0.22; P < 0.01). A concomitant decrease in prostacyclin production was seen (51.6±12.6 pmol/mg in infants of diabetic mothers vs. 71±22.3 in controls). Moreover, an inverse correlation between these two eicosanoids was also noted. Our results suggest a potential in vivo regulatory role for 15-HETE on prostacyclin production.
1 5-Hydroperoxy-5,8, 11,13-eicosatetraenoic acid has been found to enhance the release of anaphylactic mediators from guinea pig lung (1) , and to block prostacyclin synthetase (2) . These biologic activities however have not been described for the corresponding hydroxyacid, 1 5-hydroxy-5,8, 11,1 3-eicosatetraenoic acid (1 5-HETE).' We have recently reported that 15-HETE (a major lipoxygenase metabolite of arachidonic acid in human endothelial cells [3] , leukocytes [4] , and lung [5] ) enhances endothelial cell migration (6) , an initial and obligatory step in angiogenesis and neovascular proliferation (7, 8) . In this report we provide evidence that 15-HETE is a competitive inhibitor of vascular cyclooxygenase, is the major lipoxygenase metabolite in human vasculature, and is significantly increased in vessels obtained from the diabetic milieu. Our results suggest a potential role for this hydroxyacid as an endogenous regulator of vascular prostacyclin biosynthesis.
Methods
Materials 15-HETE was prepared by incubating arachidonic acid with soybean lipoxygenase (9) . 12-HETE was prepared by incubating arachidonic acid with indomethacin-treated platelets (10) . The resulting hydroperoxy derivatives were reduced to the respective hydroxy acids using triphenyl phosphine and then sodium borohydride (11) . Both 15-HETE and 12-HETE were purified by silicic acid column chromatography followed by reverse-phase high pressure liquid chromatography (HPLC) and then stored at -70'C in methanol. The purity ofthese preparations was >99%, as tested by analytical reverse-phase HPLC and ultraviolet absorption spectroscopy. The structures were confirmed by gas chromatographymass spectroscopy (GC-MS). The mass spectrum of the trimethyl silyl ether methyl ester of 15-HETE showed prominent ions (M+, molecular ion; the relative abundance and probable mode of origin are given in parentheses) at the mass-to-charge ratio (m/e) 335 (4%, M+- 7 1 Umbilical cords were obtained from control infants (n = 9) at the time of delivery, and from infants of diabetic mothers (IDM; n = 11) of comparable gestational age. Classification of maternal diabetes mellitus was established according to standard criteria and included class A (n = 2), class B (n = 6), class C (n = 1), class D (n = 1), and class R (n = 1). No control or diabetic mother had ingested aspirin within 2 wk of delivery, and the mean gestational ages in both groups was similar (38.8±0.9 for controls vs. 38.2±1.2 for diabetics). This study was approved by the Human Institutional Experimentation Committee.
Metabolism ofarachidonic acid by intact human umbilical arterial segments to prostaglandins and HETEs and their identification The umbilical cords were dissected at ice temperature and the arteries were isolated, cut into 5-mm segments, and opened longitudinally before use. Histologic sections of the vessels were concomitantly evaluated revealing an intact endothelial layer in all arteries studied. The arterial segments were suspended in Tris-buffered CMFH, pH 7.4, with calcium chloride (5 For structural identification, HETEs were prepared by incubating the intact arterial segments with either labeled or unlabeled arachidonic acid as described above. The products were purified by silicic acid column chromatography and analyzed by reverse-phase HPLC in methanol-0.1% acetic acid (72:28, by vol) using a 4.6 X 250-mm Waters C-18 column (Waters Associates, Milford, MA) and a Beckman liquid chromatograph (Beckman Instruments, Inc., Palo Alto, CA). The flow rate was 1 ml per min. The column effluent was monitored continuously at 237 nm (for the elution of mono-HETEs) and 270 nm (for di-HETE elution) with a Beckman model 165 variable wavelength detector. For radiolabeled products, 0.5-ml fractions were collected, a 0.25-ml aliquot from each fraction was counted, and the remaining peak fractions were pooled, individually rechromatographed in the same system, and analyzed on silica gel G plates in the hexane-ether-acetic acid solvent system. For GC-MS analysis, the unlabeled metabolites were purified by silicic acid column chromatography followed by reverse-phase HPLC (20) . Cells (passages 10-17) from confluent cultures were de-gently rinsed with 2.5 ml of CMFH. The cells were then incubated with prewarmed control or test medium. All experiments were done in serumfree medium at 370C in an atmosphere of 5% CO2 in air.
Basal or bradykinin-stimulted release of6kPGF1,. 15 As depicted in Fig. 3 , ETYA (60 uM), an inhibitor of both the cyclooxygenase and lipoxygenase pathways (24), inhibited the production of prostaglandins (71±9% [1 SE]; P < 0.01) as well as the vascular HETEs including 11-HETE (98±2%; P < 0.05), 15-HETE (71±15%; P < 0.01) and the di-HETE (61±16%; P <0.05). NDGA, a lipoxygenase inhibitor (25) showed differential inhibitory effects on vascular HETE production. At a concentration of 30 gM, NDGA inhibited 15-HETE production by 66±6% (P < 0.01) whereas it stimulated the production of prostacyclin, total prostanoids, 1 1-HETE, and the di-HETE by 86±25%, 52±25%, 160+60%, and 49±10% over control values, respectively (P < 0.05 to P < 0.01). Similar effects of NDGA were also noted at a concentration of 15 uM (data not shown). Indomethacin (30 pM) significantly inhibited prostacyclin, total prostanoids, 11-HETE, and di-HETE production by 83±7%, 78+8% 98+2%, and 81±9%, respectively (P < 0.01).
15-HETE production was only minimally inhibited (20±3%; P = 0.05). These results indicate that, whereas 11-HETE and the di-HETEs are enzymatic products of cyclooxygenase in human umbilical arteries, 15 -HETE is mainly a lipoxygenase product with minimal production of this metabolite occurring via cyclooxygenase. Table I summarizes the conversion of radiolabeled arachidonic acid to various metabolites by intact human umbilical arteries. Prostacyclin was the major metabolite of arachidonic acid in these tissue preparations. Significant amounts of PGF2a, PGE2, di-HETEs, and 1 5-HETE were also generated. The ratio of prostacyclin to 1 5-HETE was -6: 1.
Inhibition ofprostaglandin production by 15-HETE Stimulation ofprostacyclin production by a lipoxygenase inhibitor with a concomitant inhibition of 1 5-HETE production suggested to us that lipoxygenase metabolites of arachidonic acid could function as endogenous regulators of prostacyclin production in human vascular tissue. We therefore studied the metabolism of arachidonic acid by human umbilical arterial microsomal cyclooxygenase in the presence or absence of 1 5-HETE.
Whereas the production of 6kPGFIa was inhibited by 15-HETE (Fig. 4 A) , the relative distribution among the prostaglandins was essentially unaltered. The ratios of 6kPGFIa to PGF2cx to PGE2 produced was 3:1:1 in both control and 1 5-HETE-treated microsomes. These results suggested that 15-HETE inhibited cyclooxygenase. The inhibition was concentration-dependent with an IC50 of 52±3 (mean± 1 SE) and 63±4 gM for 6kPGFia and total prostanoid formation, respectively (Fig. 4 A) . At concentrations of 25, 50, and 100 ,M 1 5-HETE, inhibition of vascular 6kPGF1Q production was 22%, 52%, and 76%, respectively (P < 0.01). Inhibition of total prostanoid production by 15- HETE was found to parallel that observed for 6kPGFIa (12%, 42%, and 69% respectively). We also tested the effects of 11-HETE, another mono-HETE made by vascular segments; 12-HETE the platelet lipoxygenase product; and ricinoleic acid, a C18 hydroxy fatty acid on vascular cyclooxygenase activity (Fig.  4 B) . Both 1 1-HETE and 1 2-HETE were found to inhibit total prostanoid production (with a parallel decrease in 6kPGFIa) with IC50 of 74 and 78 ,uM, respectively. Ricinoleic acid had no effect on microsomal prostanoid production.
Conditions for the kinetic analyses of human umbilical arterial cyclooxygenase were previously established (19) . Kinetic analyses of 1 5-HETE inhibition of arterial microsomal cyclooxygenase revealed that the Vmax of the conversion of arachidonic acid to prostaglandins remained essentially unaltered. The apparent affinity of the enzyme for substrate (apparent Km) was, however, decreased in the presence of 1 5-HETE. Such changes were seen in each of the five different experiments, a representative example of which is depicted in Fig. 5 . The results of all experiments are seen in Table II . The mean V.m remained unaltered whereas the apparent Km was significantly different (P < 0.05) in the paired 1 5-HETE-treated microsomes (37.6±17.7 ,uM, I SD) when compared to the control microsomes ( 71±22.3 pmol in controls; P < 0.05) was noted. An inverse correlation was also observed between endogenous production of 6kPGF1, and 1 5-HETE (r = -0.60; P < 0.02; Fig. 6 ). Effect of 15-HETE on endothelial cell arachidonic acid metabolism Effect of 15-HETE on the release ofimmunoreactive 6kPGFIa.
Incubation of bovine endothelial cells with MEM led to the appearance in the medium of prostacyclin measured immunologically as its stable hydrolysis product 6kPGFia. The appearance of 6kPGFIa in the medium increased markedly in the first 10 min after the addition of fresh serum-free medium and rose more slowly up to 60 min remaining essentially unchanged thereafter (Fig. 7 A) . When the endothelial cells were stimulated Total prostanoids are the sum of 6kPGF1,, PGF2a, PGE2, TXB2, and PGI2 production. Total prostacyclin is the sum of 6kPGFia and PGI2 production.
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with bradykinin, the release of immunoreactive 6kPGF1,< increased two-to three-fold (Fig. 7 B) . Basal release of 6kPGFI,, was inhibited by 65% and 85% in the presence of 50 and 100 jiM 1 5-HETE, respectively, at 60 min. Bradhykinin-stimulated release was also inhibited (83%) by 1 5-HETE at 60 min.
Inhibition of endothelial cell cyclooxygenase by We studied the metabolism of exogenous [1-'4C] arachidonic acid by intact endothelial cells in the presence or absence of 1 5-HETE. The production of prostacyclin as well as total prostanoids was inhibited by 15 -HETE in a parallel concentration-dependent manner (Fig. 8) . The IC50 for prostacyclin and total prostanoid formation were 39.6±16.9 uM (mean±l SD) and 36.9±13.7 juM, respectively. When similar concentrations of 1 2-HETE and ricinoleic acid (1-100 ,uM) were tested for their effects on endothelial cell arachidonic acid metabolism, 12-HETE was found to inhibit total prostanoid formation with an IC50 of 80 ,uM, whereas ricinoleic acid had no effect on prostaglandin formation (data not shown).
1 5-HETE also inhibited endothelial cell cyclooxygenase activity in isolated microsomes. Kinetic analyses of 1 5-HETE inhibition of microsomal cyclooxygenase revealed that the Vma ofprostaglandin formation remained essentially unaltered (1,100 pmol/mg -min control vs. 1,130 pmol/mg min for 15-HETEtreated enzyme). The apparent affinity of the enzyme for substrate (apparent Ki) was decreased in the presence of 1 5-HETE (5.7 AM for control vs. 17.0 ,uM for 15-HETE-treated enzyme) (Fig. 9) . The inhibition constant (Ki) for 1 5-HETE against bovine endothelial cell microsomal cyclooxygenase was estimated from a Dixon plot (26) to be 43 MM (Fig. 9, inset) tabolites was observed. Thus, although 1 5-HETE did not inhibit arachidonic acid mobilization from phospholipids, it did affect the metabolic fate of the mobilized arachidonic acid.
Discussion
Intact human umbilical arteries generated prostaglandins as well as mono-, and di-HETEs from arachidonic acid. The major product ofarachidonic metabolism was prostacyclin. The arterial mono-HETEs were identified by reverse-phase HPLC and G0-MS as 1 1-HETE and 1 5-HETE and these were produced in the ratio of 1:6. Our results also suggest that both mono-and diHETEs are enzymatically generated in arterial segments, with 15-HETE being the major lipoxygenase metabolite. A minor portion ('-20%) oftotal 15-HETE production together with 1 of 1 5-HETE via the 1 5-lipoxygenase pathway has also been reported by others in cultured human umbilical endothelial cells (3) . Our initial exeriments with inhibitors also suggested that endogenous products of the lipoxygenase reaction could modulate the production of prostacyclin in vascular tissue. This suggestion was supported by our observation that NDGA stimulated prostacylcin with a concomitant inhibition in the production of 1 5-HETE (Fig. 3) release of arachidonic acid from cellular phospholipids in response to the calcium ionophore A23 187 stimulation remained largely unchanged, substantial amounts of radiolabel accumulated in neutral lipids. This could be due to the increased availability of free arachidonic acid for the synthesis of triglycerides, which may play an important role in the turnover of arachidonic acid in endothelial cells (27) . Other mono-HETEs including 11-and 12-HETE elicit similar inhibitory effects on vascular cyclooxygenase, although 1 5-HETE is the principal monoHETE, and appears to be the only metabolite produced by the lipoxygenase pathway in human vasculature tissue. That our in vitro findings on the effects of 1 5-HETE on vascular cyclooxygenase activity may be relevant to the in vivo situation was further studied in a human pathalogic state known to be associated with abnormal vascular prostacyclin production. For these final studies we chose pathalogic vascular tissue obtained from the diabetic milieu, i.e., the infant of the diabetic mother (IDM). We found that vascular tissue obtained from the IDM produced Figure 9 . Kinetic analyses of inhibition by 15 Based on our findings, we suggest that the hydroxy acid 15-HETE could potentially play a role in vascular pathologic states associated with both macrovascular and microvascular changes, as occurs in diabetes mellitus. Vascular disease is the major cause of morbidity and mortality in diabetes, and includes both large vessel disease (atherosclerotic or macrovascular), and abnormalities affecting the capillaries, i.e., diabetic "microangiopathy" (28) . Both in humans with diabetes mellitus and in the animal model, abnormalities in platelet-vascular arachidonic acid metabolism have been observed that may contribute to the development of atherosclerotic or macrovascular disease. These include enhanced platelet production of proaggregatory TXA2, together with a decrease in vascular prostacyclin production (29) (30) (31) (32) . The term microangiopathy hides a fundamental lack of knowledge regarding the basic biochemical and cellular level changes that affect the retinal and glomerular capillaries in this disease. Diabetic retinopathy begins with the formation of microaneurysms and ultimately leads to neovascularization and proliferative retinopathy, a cause of vitreous hemorrhage, retinal detachment, and blindness (33) . We have previously shown that 1 5-HETE enhances endothelial cell migration in vitro, and elicits neovascularization in an in vivo angiogenic system, i.e., the rabbit corneal pocket assay (6) . An increase in 15-HETE production in diabetes mellitus could therefore not only modulate endogenous vascular prostacyclin production, but could also play a role in the abnormal neovascularization observed in the microcirculation of the patient with diabetes. The umbilical vessels offer an unique opportunity to evaluate vascular tissue obtained from normal and various pathologic environments. Moreover, because the IDM has been observed to exhibit both an increased incidence of thromboses and thromboembolic phenomena (34, 35), together with abnormalities ofthe microcirculation (36) , changes observed in IDM vasculature may closely simulate those observed in the adult with diabetes mellitus. In a previous study of platelets from IDM, we had demonstrated that the metabolism of arachidonic acid by the neonatal platelet at birth accurately reflected diabetic maternal platelet arachidonate metabolism (37) . The presence of increased amounts of 15-HETE in vasculature obtained from the diabetic milieu with a concomitant decrease in 6kPGFI. formation may therefore be of potential significance, and point the way to further studies on the diabetic patient himself.
The studies of Vanderhoek (38) have recently begun to elucidate a possible regulatory role for 1 5-HETE in the formation of lipoxygenase arachidonate metabolites in platelets, polymorphonuclear leukocytes, and T lymphocytes. This author has demonstrated that 1 5-HETE is a selective inhibitor of platelet lipoxygenase. This hydroxy acid was also found to inhibit the formation ofthe 5-lipoxygenase arachidonic acid metabolites in rabbit leukocytes, and in human T lymphocytes. Our observation that 1 5-HETE is a competitive inhibitor of vascular cyclooxygenase, and that this compound is increased in vasculature obtained from the diabetic milieu (a disease state associated with vascular pathology and decreased prostacyclin production), should lay the groundwork for future investigations into the role of 15-HETE as an endogenous regulator of prostacyclin and neovascularization in various disorders associated with vascular pathology.
